A Multicenter Prospective Registry of Systemic Therapy for Unresectable Hepatocellular Carcinoma with Linked Multi-omics Biobanking and Translational Validation

A Multicenter Prospective Registry of Systemic Therapy for Unresectable Hepatocellular Carcinoma with Linked Multi-omics Biobanking and Translational Validation - LIORA (Liver cancer Immuno-Oncology biomarker Research Action)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059241

Enrollment

1000

Registered

2025-10-01

Start date

2025-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged over 20 years 2. Life expectancy of >12 weeks 3. Hepatocellular carcinoma diagnosed by histology, cytology or by imaging such as dynamic contrast enhanced CT or MRI 4. Not amenable to locoregional therapy and eligible for systemic pharmacotherapy 5. ECOG Performance Status 0 or 1 6. No contraindications to the planned agents per the approved package insertm, prescribing information

Exclusion criteria

Exclusion criteria: 1. Patients from whom informed consent cannot be obtained 2. Patients deemed unsuitable for the study by the principal investigator or a subinvestigator

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS)	—

Secondary

Measure	Time frame
Factors associated with the efficacy of systemic anticancer therapy including clinical data and blood- and tissue-based biomarkers, including genomic data that qualify as personally identifiable codes ,with respect to ORR, PFS, and OS Progression-Free Survival Objective Response Rate Correlation between pre-/post-treatment changes in biomarkers and treatment efficacy Incidence and severity of adverse events, graded per CTCAE v5.0	—

Measure

Time frame

Factors associated with the efficacy of systemic anticancer therapy including clinical data and blood- and tissue-based biomarkers, including genomic data that qualify as personally identifiable codes ,with respect to ORR, PFS, and OS Progression-Free Survival Objective Response Rate Correlation between pre-/post-treatment changes in biomarkers and treatment efficacy Incidence and severity of adverse events, graded per CTCAE v5.0

—

Countries

Japan

Contacts

Public ContactYuta Myojin

The University of Osaka, graduate school of medicine Department of gastroenterology and hepatology

myojin@gh.med.osaka-u.ac.jp0668793621

Outcome results